Literature DB >> 2657153

Cyclosporine-associated microangiopathic hemolytic anemia in a renal transplant recipient.

N Yoshimura1, T Oka, Y Ohmori, I Aikawa, T Yasumura, S Matsui, T Hamashima, C J Lee.   

Abstract

A case of microangiopathic hemolytic anemia (MHA) associated with the immunosuppressive agent, cyclosporine, is reported herein. The patient manifested anemia with red blood cell fragmentation, hypertension, thrombocytopenia, elevation of serum LDH levels and glomerular capillary thromboses within a few days of his transplantation. Extensive treatments with urokinase and heparin proved ineffective and graftectomy was performed 7 days after his transplantation. Immunofluorescent staining failed to show immunoglobulin (IgG or IgM) or complement (C3) deposition within the glomeruli, which discriminated MHA from acute humoral-vascular rejection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2657153     DOI: 10.1007/bf02471590

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  12 in total

1.  Cyclosporine-associated microangiopathy in renal transplantation: a severe but potentially reversible form of early graft injury.

Authors:  J A Walfe; R L McCann; F Sanfilippo
Journal:  Transplantation       Date:  1986-04       Impact factor: 4.939

2.  Hypertension and convulsions in children receiving cyclosporin A.

Authors:  D V Joss; A J Barrett; J R Kendra; C F Lucas; S Desai
Journal:  Lancet       Date:  1982-04-17       Impact factor: 79.321

3.  Hypertension in renal transplant recipients on cyclosporin A and corticosteroids and azathioprine.

Authors:  D V Hamilton; D J Carmichael; D B Evans; R Y Calne
Journal:  Transplant Proc       Date:  1982-09       Impact factor: 1.066

4.  Preliminary experience with cyclosporin A in human renal allografts.

Authors:  O N Fernando; P Sweny; K Farrington; H Rogers; R A Baillod; M K Chan; Z Varghese; J F Moorhead
Journal:  Transplant Proc       Date:  1980-06       Impact factor: 1.066

5.  Cyclosporin A hepatotoxicity in 66 renal allograft recipients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Transplantation       Date:  1981-12       Impact factor: 4.939

6.  Identification and treatment of cyclosporine-associated allograft thrombosis.

Authors:  R E Schlanger; M L Henry; B G Sommer; R M Ferguson
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

7.  Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?

Authors:  G Remuzzi; R Misiani; D Marchesi; M Livio; G Mecca; G de Gaetano; M B Donati
Journal:  Lancet       Date:  1978-10-21       Impact factor: 79.321

8.  Nephrotoxicity in bone marrow transplant recipients treated with cyclosporin A.

Authors:  J M Hows; P M Chipping; S Fairhead; J Smith; A Baughan; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

9.  Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes.

Authors:  K Atkinson; J C Biggs; J Hayes; M Ralston; A J Dodds; A J Concannon; D Naidoo
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

10.  Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury.

Authors:  H Shulman; G Striker; H J Deeg; M Kennedy; R Storb; E D Thomas
Journal:  N Engl J Med       Date:  1981-12-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.